Vascular Biogenics Ltd. logo
Vascular Biogenics Ltd. VBLT

Quarterly report 2024-Q2
added 08-14-2024

report update icon

Vascular Biogenics Ltd. Cash Flow 2011-2026 | VBLT

Annual Cash Flow Vascular Biogenics Ltd.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-13.7 M -11.6 M -25 M -23.4 M -13.1 M -15.7 M - - - - - - -

Depreciation & Amortization

257 K 323 K 1.26 M 1.19 M 1.22 M 1.16 M - - - - - - -

Accounts Payables

1.76 M 753 K 4.33 M 1.96 M - - - - - - - - -

Accounts Receivables

186 K 8 K 185 K 6 K - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Vascular Biogenics Ltd.

2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- -3.56 M - - - -2.92 M - - - -8.3 M - - - -6.01 M - - - -5.94 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

- 63 K - - - 68 K - - - 338 K - - - 296 K - - - 301 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

1.14 M 1.52 M 1.76 M 748 K 718 K 1.1 M 808 K - - 6.19 M 4.33 M 2.33 M 2.49 M 1.6 M 1.96 M - - - 3.33 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

184 K 183 K 186 K - - - - - - - 185 K - - - 6 K - - - 424 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Vascular Biogenics Ltd., reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.5 0.45 % $ 862 M canadaCanada
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 3.83 1.32 % $ 105 M schweizSchweiz
Agenus Agenus
AGEN
$ 3.64 9.31 % $ 108 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 35.08 -0.36 % $ 2.03 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.39 0.36 % $ 357 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.95 -11.63 % $ 266 B britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 1.57 -5.42 % $ 94.3 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
$ 8.08 1.38 % $ 79.9 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 331.14 3.85 % $ 43.4 B usaUSA
Altimmune Altimmune
ALT
$ 3.4 1.8 % $ 300 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
$ 1.99 0.81 % $ 107 M usaUSA
Amgen Amgen
AMGN
$ 344.03 -1.12 % $ 185 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.27 -1.68 % $ 3.85 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.99 1.28 % $ 220 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 73.8 -0.55 % $ 1.43 B usaUSA
Annexon Annexon
ANNX
$ 5.56 1.0 % $ 862 M usaUSA
Annovis Bio Annovis Bio
ANVS
$ 2.56 12.28 % $ 52.6 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 -5.16 % $ 4.8 M chinaChina
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
$ 0.7 -1.87 % $ 4.58 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.12 -0.24 % $ 441 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.14 1.31 % $ 223 M israelIsrael
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ardelyx Ardelyx
ARDX
$ 5.99 0.84 % $ 1.44 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
argenx SE argenx SE
ARGX
$ 749.99 0.48 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.06 1.82 % $ 3.06 B usaUSA
Arvinas Arvinas
ARVN
$ 10.87 0.14 % $ 771 M usaUSA
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 60.28 -1.23 % $ 8.06 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
$ 29.51 1.72 % $ 331 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.62 1.82 % $ 8.71 B australiaAustralia